The US Food and Drug Administration (FDA) is due to issue a decision by September 26 on the approval of KarXT, a potential first-in-class antipsychotic. If approved, it would be the first drug with a ...

The EMERGENT-3 trial, published in the Journal of the American Medical Association Psychiatry, represents a significant advancement in the treatment of schizophrenia, particularly for individuals ...

New University of Pittsburgh research points to a potential approach to reducing the risk of diabetes associated with widely prescribed antipsychotic medications. The study, including experiments in ...

New University of Pittsburgh research points to a potential approach to reducing the risk of diabetes associated with widely-prescribed antipsychotic medications. This research may also explain why ...

Antipsychotic medications exert their therapeutic effects primarily through modulation of neurotransmitter systems in the brain, most notably by antagonising dopamine D2 receptors within mesolimbic ...

Xanomeline-trospium (KarXT) — a novel therapy that combines a muscarinic receptor agonist with an anticholinergic agent — led to statistically significant and clinically meaningful improvements in ...

PITTSBURGH, June 13, 2024 – New University of Pittsburgh research points to a potential approach to reducing the risk of diabetes associated with widely prescribed antipsychotic medications. The study ...

In a previous article, I made the case that little has changed within the antipsychotic drug landscape over the past 70 years since the only effective medications for the treatment of schizophrenia ...

New research points to a potential approach to reducing the risk of diabetes associated with widely prescribed antipsychotic medications. The study presents early evidence in support of ...

· Schizophrenia affects more than 2.5 million people in U.S. CHICAGO --- Antipsychotic drugs – used to treat the millions of people in the U.S. with schizophrenia — have lots of unpleasant side ...